Prospective evaluation of an anemia treatment algorithm in hemodialysis patients

被引:19
|
作者
Patterson, P [1 ]
Allon, M [1 ]
机构
[1] Univ Alabama Birmingham, Nephrol Res & Training Ctr, Birmingham, AL USA
关键词
hemodialysis; anemia; iron deficiency; treatment algorithm;
D O I
10.1016/S0272-6386(98)70028-9
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Current guidelines recommend maintaining the hematocrits of chronic hemodialysis patients in the low to mid-30s, Maintaining patients' hematocrits within a narrow range requires frequent monitoring of their hematocrits and iron studies and periodic adjustment of erythropoietin doses and administration of intravenous iron. We designed a simple anemia treatment algorithm to streamline the management of anemia in hemodialysis patients, The protocol required formal monthly decisions about the administration of intravenous iron or changes in erythropoietin dose, This algorithm was implemented by dialysis nurses and evaluated prospectively for 6 months in a single dialysis unit (30 patients). The proportion of patients whose hematocrits were within the desired target (31% to 35%) increased from 27% at baseline to 61% during months 4 through 6 of the algorithm. Conversely, the proportion of patients whose hematocrit values were below the target decreased from 46% at baseline to 18% during months 4 through 6 of the algorithm (P = 0.004). The percentage of patients whose hematocrit values were above the target did not increase. The proportion of patients whose transferrin saturation was less than 18% decreased from 47% at baseline to 20% during months 4 through 6 of the algorithm (P = 0.04). The weekly erythropoietin dose administered decreased from 11,200 +/- 1,400 units at baseline to 9,400 +/- 1,200 units in month 6 of the algorithm (P = 0.06). We conclude that a simple anemia treatment algorithm implemented by dialysis nurses is feasible and efficacious and may increase the proportion of hemodialysis patients whose hematocrit values are within the target range, without increasing erythropoietin requirements. (C) 1998 by the National Kidney Foundation, Inc.
引用
收藏
页码:635 / 641
页数:7
相关论文
共 50 条
  • [31] Absence of Anemia in Hemodialysis Patients
    Goodkin, David A.
    Fuller, Douglas S.
    Robinson, Bruce M.
    Pisoni, Ronald L.
    BLOOD PURIFICATION, 2011, 32 (03) : 209 - 209
  • [32] EVALUATION OF IRON-DEFICIENCY ANEMIA IN CHRONIC-HEMODIALYSIS PATIENTS
    WALSHE, J
    VENUTO, R
    KIDNEY INTERNATIONAL, 1977, 12 (06) : 493 - 493
  • [33] Evaluation of a biosimilar recombinant alpha epoetin in the management of anemia in hemodialysis patients
    Beiraghdar, Fatemeh
    Panahi, Yunes
    Einollahi, Behzad
    Nemati, Eghlim
    Sahebkar, Amirhossein
    Hassanzadeh, Arash
    Khosroshahi, Hamid T.
    Azar, Sima A.
    Safa, Javid
    Hashemi, Sadroddin R.
    Etemadi, Jalal
    Marzony, Eisa T.
    Noshad, Hamid
    SAUDI PHARMACEUTICAL JOURNAL, 2015, 23 (05) : 544 - 548
  • [34] Evaluation of clinical and laboratory variables associated with anemia in pediatric patients on hemodialysis
    de Freitas, Johnathan S.
    Costa, Paulo Sucasas
    Costa, Luciane Rezende
    Naghettini, Alessandra V.
    JORNAL DE PEDIATRIA, 2015, 91 (01) : 87 - 92
  • [35] THE ROLE OF FERRITIN AS AN INFLAMMATORY RESPONSE MARKER IN THE EVALUATION OF ANEMIA IN HEMODIALYSIS PATIENTS
    Pereira, Benedito Jorge
    Gelmetti, Adriana Peixoto
    Ariza, Ezequiel Rios
    Nastri, Aderbal Angelo
    NEPHROLOGY, 2005, 10 : A316 - A316
  • [36] Evaluation of the Effect of Pentoxifylline on Erythropoietin-resistant Anemia in Hemodialysis Patients
    Mohammadpour, Amir-Hooshang
    Nazemian, Fatemeh
    Khaiat, Mohammad Hassanzade
    Tafaghodi, Mohsen
    Salari, Pooneh
    Charkazi, Somaieh
    Naghibi, Masih
    Shamsara, Jamal
    SAUDI JOURNAL OF KIDNEY DISEASES AND TRANSPLANTATION, 2014, 25 (01) : 73 - 78
  • [37] Poor Compliance with Guidelines on Anemia Treatment in a Cohort of Chronic Hemodialysis Patients
    van der Weerd, Neelke C.
    Grooteman, Muriel P. C.
    Blankestijn, Peter J.
    Mazairac, Albert H. A.
    van den Dorpel, Marinus A.
    den Hoedt, Claire H.
    Nube, Menso J.
    Penne, E. Lars
    van der Tweel, Ingeborg
    ter Wee, Piet M.
    Bots, Michiel L.
    BLOOD PURIFICATION, 2012, 34 (01) : 19 - 27
  • [38] Oxidative stress in renal anemia of hemodialysis patients is mitigated by epoetin treatment
    Siems, W
    Carluccio, F
    Radenkovic, S
    Grune, T
    Hampl, H
    KIDNEY & BLOOD PRESSURE RESEARCH, 2005, 28 (5-6): : 295 - 301
  • [39] Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients
    Nissenson, AR
    Swan, SK
    Lindberg, JS
    Soroka, SD
    Beatey, R
    Wang, C
    Picarello, N
    McDermott-Vitak, A
    Maroni, BJ
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 40 (01) : 110 - 118
  • [40] CONTINUING CORRECTION OF ANEMIA BY TREATMENT WITH RECOMBINANT ERYTHROPOIETIN IN PATIENTS MAINTAINED BY HEMODIALYSIS
    COTES, PM
    PIPPARD, MJ
    REID, CDL
    OLIVER, DO
    WINEARLS, CG
    EXPERIMENTAL HEMATOLOGY, 1987, 15 (05) : 437 - 437